Shire cuts sales outlook; still considering spinout of ADHD drugs

Rare disease drugmaker Shire cut its 2020 revenue forecast on Monday, and announced that it plans to split its ADHD drugs into a separate division, with a possible spinout in the future. Shire (Nasdaq: SHPG), the state’s second largest biopharma employer, said that it is now projecting its total revenue to reach $17 billion to $18 billion by 2020. That is down from a $20 billion projection that Shire made in 2015, following its acquisition of Baxalta. Shire reported $11.4 billio n in sales in 2016. Shares…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news